Date: 2018-10-08
Type of information: Production agreement
Compound: manufacturing platform for gene therapy programs
Company: Sarepta Therapeutics (USA - MA) Paragon Bioservices (USA - MD)
Therapeutic area: Rare diseases - Genetic diseases - Technology - Services
Type agreement: manufacturing - bioproduction
Action mechanism: gene therapy
Disease:
Details:
- • On October 8, 2018, Sarepta Therapeutics announced that it has entered into a long-term strategic manufacturing partnership with Paragon Bioservices, which will provide Sarepta access to additional commercial manufacturing capacity for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program, as well as a manufacturing platform for future gene therapy programs, such as Limb-girdle muscular dystrophy (LGMD), Pompe disease and CNS.
- Paragon, one of Baltimore’s largest biotechnology companies, employs a team of 300+ at two locations in Maryland. Paragon is constructing a new, world-class, 151,000 square-foot, GMP gene therapy biomanufacturing facility, which will be online in February 2019 and is located in Anne Arundel County. It will include several 500L and 2000L single-use bioreactors for clinical trial and commercial material production. Paragon also has facilities at the University of Maryland, Baltimore (UMB) BioPark where the company currently provides full process, analytical development, and cGMP clinical manufacturing services from its approximately 100,000 square-foot facility.
Financial terms:
Latest news:
Is general: Yes
